Cytokinetics, Inc. (CYTK), a biopharmaceutical company focused on muscle biology, on Monday announced the launch of the AMBER-HFpEF trial, a Phase 2 clinical study to evaluate CK-586 in patients with symptomatic heart failure with preserved ejection fraction or HFpEF.
CK-586 is a cardiac myosin inhibitor in development for the treatment of a subgroup of HFpEF patients who exhibit hypercontractility and ventricular hypertrophy.
The AMBER-HFpEF trial is a randomized, double-blind, placebo-controlled, multi-center study designed to assess the safety, tolerability, and efficacy of CK-586.
This trial builds on promising data from previous studies in related conditions such as non-obstructive hypertrophic cardiomyopathy or nHCM.
The trial aims to provide further insights into CK-586's potential to improve heart function and symptoms in patients with HFpEF, a condition that significantly impacts quality of life and has a poor prognosis despite advances in heart failure treatments.
Cytokinetics plans to enroll approximately 60 patients across three escalating doses to evaluate CK-586's effects on key cardiovascular markers.
The trial marks a critical step in the company's goal to provide targeted, effective therapies for heart failure patients with preserved ejection fraction.
Currently, CYTK is trading at $45.70 down by 0.09%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.